Phospho-ALK (Tyr1507) Antibody [P14J22] Datasheet

Biological Description

Specificity	Phospho-ALK (Tyr1507) Antibody [P14J22] detects endogenous levels of total ALK protein only when it is phosphorylated at Tyr1507.
Background	Phospho‑ALK (Tyr1507) marks a functionally critical autophosphorylation site on the intracellular tyrosine kinase domain of anaplastic lymphoma kinase (ALK), a neuronal‑type receptor tyrosine kinase activated by ligands such as pleiotrophin and ALKAL family proteins in the nervous system and by oncogenic ALK‑fusion proteins in cancer. In the full‑length receptor, tyrosine‑1507 lies within a canonical NPXpY motif that, when phosphorylated, recruits SH2‑domain‑ and PTB‑domain‑containing adaptor proteins, most notably the docking proteins Shc, FRS2‑α, and FRS2‑β, which in turn bridge activated ALK to the Ras‑ERK (MAPK) and PI3K‑Akt signaling axes. Antibody‑mediated or ligand‑dependent activation of ALK drives phosphorylation at Tyr1507, promotes Shc and FRS2 recruitment and phosphorylation, and supports sustained ERK activation that underlies neuronal‑like differentiation and mitogenic responses. The equivalent phospho‑site (Tyr567) in the NPM‑ALK fusion is constitutively phosphorylated and required for efficient engagement of Shc and FRS2, thereby sustaining downstream proliferative and survival‑signaling pathways that contribute to lymphoma pathogenesis.

Specificity

Phospho-ALK (Tyr1507) Antibody [P14J22] detects endogenous levels of total ALK protein only when it is phosphorylated at Tyr1507.

Background

Phospho‑ALK (Tyr1507) marks a functionally critical autophosphorylation site on the intracellular tyrosine kinase domain of anaplastic lymphoma kinase (ALK), a neuronal‑type receptor tyrosine kinase activated by ligands such as pleiotrophin and ALKAL family proteins in the nervous system and by oncogenic ALK‑fusion proteins in cancer. In the full‑length receptor, tyrosine‑1507 lies within a canonical NPXpY motif that, when phosphorylated, recruits SH2‑domain‑ and PTB‑domain‑containing adaptor proteins, most notably the docking proteins Shc, FRS2‑α, and FRS2‑β, which in turn bridge activated ALK to the Ras‑ERK (MAPK) and PI3K‑Akt signaling axes. Antibody‑mediated or ligand‑dependent activation of ALK drives phosphorylation at Tyr1507, promotes Shc and FRS2 recruitment and phosphorylation, and supports sustained ERK activation that underlies neuronal‑like differentiation and mitogenic responses. The equivalent phospho‑site (Tyr567) in the NPM‑ALK fusion is constitutively phosphorylated and required for efficient engagement of Shc and FRS2, thereby sustaining downstream proliferative and survival‑signaling pathways that contribute to lymphoma pathogenesis.

Usage Information

Application

WB, IP, IF, FCM

Dilution

WB	IP	IF	FCM
1:1000	1:100	1:400	1:200

Reactivity

Human

Source

Rabbit Monoclonal Antibody

MW

80 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/23889739/
https://pubmed.ncbi.nlm.nih.gov/17274988/

Application Data

WB

Validated by Selleck

Lane 1: KARPAS-299, Lane 2: KARPAS-299 (Crizotinib, 1 μM, 1 h)